proxyvotesnow.com

Home › Companies › Arcutis Biotherapeutics, Inc. › 2024-2025

Arcutis Biotherapeutics, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Arcutis Biotherapeutics, Inc.’s Form 8-K, filed 2025-06-17 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 5Reported items
  • 215Asset managers
  • 1,142Fund votes
  • 2025-06-12Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Arcutis Biotherapeutics, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Arcutis Biotherapeutics, Inc.

These tallies are Arcutis Biotherapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-17 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arcutis Biotherapeutics, Inc. — official shareholder meeting results, meeting held 2025-06-12
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Bhaskar Chaudhuri, Ph.D. 69,994,307---- 19,137,53214,767,325 Majority: yes
Elect Director: Sue-Jean Lin 75,774,723---- 13,357,11614,767,325 Majority: yes
Elect Director: Howard G. Welgus, M.D. 66,289,952---- 22,841,88714,767,325 Majority: yes
Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers: 74,469,06013,477,5861,185,193 --14,767,325 Majority: yes

Source: Arcutis Biotherapeutics, Inc., Form 8-K, filed with the SEC on 2025-06-17 — read the filing on EDGAR.

How asset managers voted at the Arcutis Biotherapeutics, Inc. 2024-2025 meeting

Each item below shows how the 215 asset managers that disclosed a Arcutis Biotherapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Arcutis Biotherapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%AGAINST 15%
FOR: 74,469,060AGAINST: 13,477,586

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers:”): 74,469,060 for, 13,477,586 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 119,137,785 outstanding shares: 63% for, 11% against (74% of the company cast a for/against vote).

The 213 asset managers below cast 81% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 81%AGAINST 19%
FOR: 81.0%AGAINST: 18.6%ABSTAIN: 0.4%NOT VOTED: 0.0%
Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.” at Arcutis Biotherapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
SUVRETTA CAPITAL MANAGEMENT, LLC10,584,8660 00For
Frazier Life Sciences Management, L.P.9,769,5110 00For
JENNISON ASSOCIATES LLC8,744,0060 00For
Rubric Capital Management LP7,272,4830 00For
Vanguard6,988,9958,817 00For
Prudential/PGIM5,784,2390 00For
BlackRock5,546,51427,185 00For
State Street3,955,36552,235 00For
American Century02,758,726 00Against
FRANKLIN ADVISERS INC2,651,44268,940 00For
GEODE CAPITAL MANAGEMENT, LLC02,565,962 00Against
Fidelity258,2492,288,758 00Against
Ensign Peak Advisors, Inc2,001,4390 00For
Charles Schwab1,746,4560 00For
Invesco01,705,207 00Against
Paradigm Biocapital Advisors LP01,519,214 00Against
Federated Hermes1,385,2340 00For
Aberdeen01,350,068 00Against
GW&K Investment Management, LLC1,190,0090 00For
J. Goldman & Co LP1,055,8570 00For
FRANKLIN STRATEGIC SERIES965,5450 00For
Nuveen815,8160 00For
TIAA803,7170 00For
PFM Health Sciences, LP0705,685 00Against
UniSuper Management Pty Ltd700,0000 00For

Showing the 25 largest of 213 asset managers. See all 213 in the interactive database.

2. Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Bhaskar Chaudhuri, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD 21%
FOR: 69,994,307WITHHELD: 19,137,532

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Bhaskar Chaudhuri, Ph.D.”): 69,994,307 for, 19,137,532 withheld, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 119,137,785 outstanding shares: 59% for, 16% withheld (75% of the company cast a for/withheld vote).

The 60 asset managers below cast 100% of the shares they voted on this item FOR (18,555,129 for, 0 against).

FOR 67%ABSTAIN 33%
FOR: 18,555,129 (67.0%)ABSTAIN: 9,130,779 (33.0%)
Largest asset managers voting on “Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their suc” at Arcutis Biotherapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,679,1580 6,4000For
Prudential/PGIM5,192,6240 00For
BlackRock00 2,913,1150Abstain
Fidelity2,280,5580 144,8410For
American Century00 1,342,1390Abstain
FRANKLIN STRATEGIC SERIES965,5450 00For
State Street877,1160 1,1150For
Charles Schwab00 873,0710Abstain
Invesco00 826,7020Abstain
TIAA803,7170 00For
Federated Hermes683,7220 00For
Aberdeen00 675,0340Abstain
First Trust00 343,2480Abstain
Royce339,3990 00For
AMG FUNDS284,8060 00For
Equitable00 283,7400Abstain
AIG/SunAmerica00 232,8730Abstain
John Hancock182,4660 38,1640For
SEI00 200,0580Abstain
Lincoln Financial78,9000 108,5690Abstain
DRIEHAUS MUTUAL FUNDS00 179,6950Abstain
QUANTITATIVE MASTER SERIES LLC00 143,8790Abstain
WESMARK FUNDS00 102,7000Abstain
Lazard00 83,3020Abstain
RBB FUND, INC.00 79,1980Abstain

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

3. Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Howard G. Welgus, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%
FOR: 66,289,952WITHHELD: 22,841,887

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Howard G. Welgus, M.D.”): 66,289,952 for, 22,841,887 withheld, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 119,137,785 outstanding shares: 56% for, 19% withheld (75% of the company cast a for/withheld vote).

The 60 asset managers below cast 100% of the shares they voted on this item FOR (16,811,560 for, 0 against).

FOR 61%ABSTAIN 39%
FOR: 16,811,560 (60.7%)ABSTAIN: 10,874,348 (39.3%)
Largest asset managers voting on “Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their suc” at Arcutis Biotherapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,679,1580 6,4000For
Prudential/PGIM5,192,6240 00For
BlackRock00 2,913,1150Abstain
Fidelity2,280,5580 144,8410For
American Century00 1,342,1390Abstain
FRANKLIN STRATEGIC SERIES965,5450 00For
State Street2,4820 875,7490Abstain
Charles Schwab00 873,0710Abstain
Invesco00 826,7020Abstain
TIAA00 803,7170Abstain
Federated Hermes683,7220 00For
Aberdeen00 675,0340Abstain
First Trust00 343,2480Abstain
Royce339,3990 00For
AMG FUNDS284,8060 00For
Equitable00 283,7400Abstain
AIG/SunAmerica00 232,8730Abstain
John Hancock182,4660 38,1640For
SEI00 200,0580Abstain
Lincoln Financial39,6290 147,8400Abstain
DRIEHAUS MUTUAL FUNDS00 179,6950Abstain
QUANTITATIVE MASTER SERIES LLC00 143,8790Abstain
WESMARK FUNDS00 102,7000Abstain
Lazard00 83,3020Abstain
RBB FUND, INC.00 79,1980Abstain

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

4. Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Sue-Jean Lin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%
FOR: 75,774,723WITHHELD: 13,357,116

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Sue-Jean Lin”): 75,774,723 for, 13,357,116 withheld, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 119,137,785 outstanding shares: 64% for, 11% withheld (75% of the company cast a for/withheld vote).

The 60 asset managers below cast 100% of the shares they voted on this item FOR (23,074,749 for, 0 against).

FOR 83%ABSTAIN 17%
FOR: 23,074,749 (83.3%)ABSTAIN: 4,611,159 (16.7%)
Largest asset managers voting on “Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their suc” at Arcutis Biotherapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,679,1580 6,4000For
Prudential/PGIM5,192,6240 00For
BlackRock2,913,1150 00For
Fidelity2,417,1990 8,2000For
American Century00 1,342,1390Abstain
FRANKLIN STRATEGIC SERIES965,5450 00For
State Street2,4820 875,7490Abstain
Charles Schwab873,0710 00For
Invesco826,7020 00For
TIAA803,7170 00For
Federated Hermes683,7220 00For
Aberdeen00 675,0340Abstain
First Trust00 343,2480Abstain
Royce339,3990 00For
AMG FUNDS284,8060 00For
Equitable170,3800 113,3600For
AIG/SunAmerica00 232,8730Abstain
John Hancock182,4660 38,1640For
SEI200,0580 00For
Lincoln Financial39,6290 147,8400Abstain
DRIEHAUS MUTUAL FUNDS00 179,6950Abstain
QUANTITATIVE MASTER SERIES LLC143,8790 00For
WESMARK FUNDS00 102,7000Abstain
Lazard00 83,3020Abstain
RBB FUND, INC.00 79,1980Abstain

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

5. To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

AUDIT-RELATED

100% fund support · no official result

FOR 99.9%

The 60 asset managers below cast 100% of the shares they voted on this item FOR (27,679,467 for, 0 against).

FOR: 27,679,467 (100.0%)ABSTAIN: 6,441 (0.0%)
Largest asset managers voting on “To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as ” at Arcutis Biotherapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,685,5580 00For
Prudential/PGIM5,192,6240 00For
BlackRock2,913,1150 00For
Fidelity2,425,3990 00For
American Century1,342,1390 00For
FRANKLIN STRATEGIC SERIES965,5450 00For
State Street878,2310 00For
Charles Schwab873,0710 00For
Invesco826,7020 00For
TIAA803,7170 00For
Federated Hermes683,7220 00For
Aberdeen675,0340 00For
First Trust343,2480 00For
Royce339,3990 00For
AMG FUNDS284,8060 00For
Equitable283,7400 00For
AIG/SunAmerica232,8730 00For
John Hancock220,6300 00For
SEI200,0580 00For
Lincoln Financial187,4690 00For
DRIEHAUS MUTUAL FUNDS179,6950 00For
QUANTITATIVE MASTER SERIES LLC143,8790 00For
WESMARK FUNDS102,7000 00For
Lazard83,3020 00For
RBB FUND, INC.79,1980 00For

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

Largest Arcutis Biotherapeutics, Inc. shareholders voting in 2024-2025

Ranked by the number of Arcutis Biotherapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 119,137,785 shares outstanding at the time of that meeting.

Top Arcutis Biotherapeutics, Inc. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1SUVRETTA CAPITAL MANAGEMENT, LLC 8.88%
2Frazier Life Sciences Management, L.P. 8.20%
3JENNISON ASSOCIATES LLC 7.34%
4Rubric Capital Management LP 6.10%
5Vanguard 5.87%
6Prudential/PGIM 4.86%
7BlackRock 4.68%
8State Street 3.36%
9American Century 2.32%
10FRANKLIN ADVISERS INC 2.28%

Reported Arcutis Biotherapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Arcutis Biotherapeutics, Inc. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
Suvretta Capital Management, LLC 8.00% DEF14A
BlackRock 7.46% 13F
Patrick J. Heron 7.38% DEF14A
Frazier Life Sciences VIII, L.P. 7.37% 13D
Rubric Capital Management LP 6.94% 13G
Vanguard Group 5.72% 13F
Polar Capital Holdings Plc 5.29% DEF14A
PRUDENTIAL FINANCIAL INC 4.45% 13G
Jennison Associates LLC 4.18% 13G
State Street 3.76% 13F

Percentages above are of 119,137,785 shares outstanding, as reported by Arcutis Biotherapeutics, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcutis Biotherapeutics, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Arcutis Biotherapeutics, Inc.'s shareholder meeting held 2025-06-12, in the 2024-2025 proxy season, 215 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,142 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — FOR was 85% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcutis Biotherapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-17.

Arcutis Biotherapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.